ViroGates accelerates commercialization of its products to aid emergency departments in prioritizing patient care.
Following extensive clinical validation and clinical utility studies in more than 300,000 patients, suPARnostic® is now being tested in numerous clinical emergency departments across Europe.
“Increased health care spending is a tremendous challenge for healthcare systems worldwide.
ViroGates helps clinicians in their daily decision making in connection with admission or discharge of patients. This way, the healthcare systems can allocate resources more effectively” says Jakob Knudsen, CEO, ViroGates.
The company has appointed Dr. Thomas Krarup as VP Sales & Marketing to lead the international clinical rollout.
ViroGates is currently evaluating different options for funding of its commercial execution.
For more information, please see Press Release here
For yderligere information, se Pressemeddelelsen her
Plese find the Danish article in MedWatch “Biotekselskab fra Birkerød ruller blodtest ud på europæiske hospitaler” here